Brain
Expert Pharmacologist
- Joined
- Jul 6, 2021
- Messages
- 264
- Reaction score
- 295
- Points
- 63
Treatment for opioid use disorder must take into account changing cannabis policies to maximize people's opportunities for recovery.
The United States is experiencing a severe overdose epidemic that was initially caused by the abuse of pain pills and then took the lives of many due to heroin and the synthetic opioid fentanyl.
According to the Centers for Disease Control and Prevention, more than 81,000 deaths were reported last year due to opioid overdoses.
The United States is experiencing a severe overdose epidemic that was initially caused by the abuse of pain pills and then took the lives of many due to heroin and the synthetic opioid fentanyl.
According to the Centers for Disease Control and Prevention, more than 81,000 deaths were reported last year due to opioid overdoses.
Millions of Americans suffer from an opioid use disorder, yet as of 2021, four out of five of them were not receiving the necessary treatment. This explains the critical need to expand access to medication-assisted therapy to help people recover.
One of the major barriers to effective treatment is the restriction of cannabis use for potential patients. Currently, many programs helping people with opioid use disorder require participants to abstain from cannabis use in order to be eligible for treatment. This approach highlights a serious mistake in the field of addiction medicine: our conservative stance on cannabis often leads to the exclusion of people from programs that can help them.
One of the major barriers to effective treatment is the restriction of cannabis use for potential patients. Currently, many programs helping people with opioid use disorder require participants to abstain from cannabis use in order to be eligible for treatment. This approach highlights a serious mistake in the field of addiction medicine: our conservative stance on cannabis often leads to the exclusion of people from programs that can help them.
We have neglected to research the potential of cannabinoids without noticing that some of them may have therapeutic benefits. Such short-sighted policies have deprived thousands of people of the help they need and overlooked the potential of cannabis for public health.
To effectively address the opioid crisis, we need to rethink our attitudes towards cannabis and develop more inclusive and effective treatments, carefully analyzing the risks and benefits.
Over the past decade, attitudes towards cannabis in the United States have undergone significant changes as the opioid crisis has escalated. Cannabis has become the fourth most popular psychoactive substance in the world after alcohol, caffeine and tobacco and contains more than 550 different components, the best known of which are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
So far, 38 states and Washington, D.C., have legalized the medical use of cannabis, and some states have even recognized opioid use disorder as a basis for medical use, though reliable data is still scarce.
To effectively address the opioid crisis, we need to rethink our attitudes towards cannabis and develop more inclusive and effective treatments, carefully analyzing the risks and benefits.
Over the past decade, attitudes towards cannabis in the United States have undergone significant changes as the opioid crisis has escalated. Cannabis has become the fourth most popular psychoactive substance in the world after alcohol, caffeine and tobacco and contains more than 550 different components, the best known of which are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
So far, 38 states and Washington, D.C., have legalized the medical use of cannabis, and some states have even recognized opioid use disorder as a basis for medical use, though reliable data is still scarce.
The Biden administration recently proposed reclassifying cannabis as a less harmful substance at the federal level, which would effectively legalize its use for medical purposes across the country. This reclassification may represent a major change in federal policy, but the new regulation is at odds with traditional approaches to the treatment of opioid-related disorders.
In the United States, methadone, which is a lifesaving medication for opioid use disorder, is dispensed through federally regulated programs that prevent this addiction. These specialized clinics provide daily doses of methadone, as well as counseling and other support.
However, many have strict abstinence policies that deny treatment to people who are found to have cannabis or its components. This prohibition is based on the assumption that cannabis can interfere with the recovery process.
In the United States, methadone, which is a lifesaving medication for opioid use disorder, is dispensed through federally regulated programs that prevent this addiction. These specialized clinics provide daily doses of methadone, as well as counseling and other support.
However, many have strict abstinence policies that deny treatment to people who are found to have cannabis or its components. This prohibition is based on the assumption that cannabis can interfere with the recovery process.
With the increasing legalization of cannabis and changing public opinion, it is evident that traditional abstinence policies are becoming increasingly distant from the growing acceptance of cannabis in society. The emergence of the concept of «California Sober», in which people give up alcohol and other drugs but continue to use cannabis, further emphasizes this disconnect.
Abstinence policies are based on the perception that cannabis use may negatively impact the treatment of opioid use disorder. However, new evidence, including results from recent systematic reviews and a meta-analysis conducted in January, refutes this view.
The recent study, which covers 4-15 months of follow-up data, found no significant association between cannabis use and relapse to non-medical opioid use among those in treatment. These findings compel a reconsideration of the role of cannabis and its cannabinoids in the recovery process, as well as a reevaluation of how policies related to cannabis use affect treatment access and retention.
Abstinence policies are based on the perception that cannabis use may negatively impact the treatment of opioid use disorder. However, new evidence, including results from recent systematic reviews and a meta-analysis conducted in January, refutes this view.
The recent study, which covers 4-15 months of follow-up data, found no significant association between cannabis use and relapse to non-medical opioid use among those in treatment. These findings compel a reconsideration of the role of cannabis and its cannabinoids in the recovery process, as well as a reevaluation of how policies related to cannabis use affect treatment access and retention.
Some mechanistic studies suggest that cannabis and its components may have positive effects in the therapy of opioid use disorder. For example, the absence of some studies indicates that THC can reduce the need for opioids in the treatment of pain, and CBD may help reduce drug-seeking behavior and cravings caused by external stimuli.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117273/
However, more research is needed to confirm these findings. Very impressive steps must be overcome before any component of cannabis can be considered an approved treatment for opioid use disorder.
In order for a drug to receive FDA approval, it must pass a rigorous gold standard evaluation: randomized, double-blind, placebo-controlled clinical trials involving human subjects.In such studies, participants are randomly assigned to groups where some receive the study drug and others receive a placebo. The agency typically requires a minimum of two well-designed trials involving more than 200 people before it can begin the approval process for a new drug.To date, only a small number of studies have specifically evaluated the efficacy and safety of cannabinoids in the treatment of opioid use disorder.
The agency typically requires a minimum of two well-designed trials involving more than 200 people before it can begin the approval process for a new drug.
To date, only a small number of studies have specifically evaluated the efficacy and safety of cannabinoids in the treatment of opioid use disorder. Therefore, until these findings are confirmed in larger studies, the idea of using cannabinoids to treat this problem should be approached with caution, relying on already tested and approved treatments.
The agency typically requires a minimum of two well-designed trials involving more than 200 people before it can begin the approval process for a new drug.
To date, only a small number of studies have specifically evaluated the efficacy and safety of cannabinoids in the treatment of opioid use disorder. Therefore, until these findings are confirmed in larger studies, the idea of using cannabinoids to treat this problem should be approached with caution, relying on already tested and approved treatments.
Recovery from opioid use disorder is a complex process. For some people, complete abstinence may be the ideal solution, but for many in the early stages of recovery, this is sometimes an unrealistic goal.
Harm reduction strategies that focus on minimizing risk provide a more compassionate and practical approach. Policy decisions that immediately exclude people from treatment programs because of their recurrent cannabis use do not take into account the complexity of recovery. Moreover, such measures may unintentionally push people to return to dangerous illicit opioids such as fentanyl and its derivatives.
Many studies show that policy changes are needed. Current evidence questions the appropriateness of zero tolerance policies that reject the possibility of treating opioid use disorder dependent on cannabis use. Yet access to life-saving medications remains critical to the recovery process.
Harm reduction strategies that focus on minimizing risk provide a more compassionate and practical approach. Policy decisions that immediately exclude people from treatment programs because of their recurrent cannabis use do not take into account the complexity of recovery. Moreover, such measures may unintentionally push people to return to dangerous illicit opioids such as fentanyl and its derivatives.
Many studies show that policy changes are needed. Current evidence questions the appropriateness of zero tolerance policies that reject the possibility of treating opioid use disorder dependent on cannabis use. Yet access to life-saving medications remains critical to the recovery process.
We emphasize that we are not calling for the use of cannabis in recovery from opioid addiction. Instead, we emphasize the need for careful and individualized assessments of the role of cannabis in therapy.
Health care providers should monitor substance use and frankly discuss with patients the impact of cannabis on their recovery, including the impact on pain, withdrawal, and the desire to use other substances for non-medical reasons.
The complex relationship between cannabis and recovery from opioid addiction needs to be explored. Future research should focus on the safety and efficacy of cannabis and its component in treating symptoms of opioid addiction, as well as how different cannabis products and consumption patterns affect treatment outcomes. Such research, combined with meaningful clinical conversations, may lead to more individualized and effective methods of care.
Health care providers should monitor substance use and frankly discuss with patients the impact of cannabis on their recovery, including the impact on pain, withdrawal, and the desire to use other substances for non-medical reasons.
The complex relationship between cannabis and recovery from opioid addiction needs to be explored. Future research should focus on the safety and efficacy of cannabis and its component in treating symptoms of opioid addiction, as well as how different cannabis products and consumption patterns affect treatment outcomes. Such research, combined with meaningful clinical conversations, may lead to more individualized and effective methods of care.